KSR antagonists

Patent metadata

Field	Value
Publication number	US-10548897-B2
Application number	US-201615566565-A
Country	US
Kind code	B2
Filing date	Apr 15, 2016
Priority date	Apr 16, 2015
Publication date	Feb 4, 2020
Grant date	Feb 4, 2020

Abstract

This invention relates to antagonists of Kinase Suppressor of Ras (KSR). Pharmaceutical compositions comprising KSR inhibitors and methods of treating cancer are also provided.

First claim

What is claimed is:

1. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, wherein:
A is selected from the group consisting of NH, N(CH 3 ), S, O, and CH 2 ;
L is selected from the group consisting of O, NH, S, and CH 2 ;
W is independently selected from the group consisting of halo and C 1-4 alkyl;
Cy 1 is selected from the group consisting of:

R 1 and R 5 are each independently selected from the group consisting of H, halo, OH, C 1-4 alkyl, and C 1-4 haloalkyl;
R 3 is selected from the group consisting of H and halo; and
R 2 and R 4 are each independently selected from the group consisting of H and halo.

2. The compound of claim 1 , wherein the compound is a compound of Formula Ib:

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

5. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

6. A method of treating a disease associated with KSR in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the patient has colon cancer.

7. The method of claim 6 , further comprising administering a therapeutically effective amount of an MEK inhibitor to the patient, wherein the MEK inhibitor is selected from the group consisting of trametinib, selumetinib, binimetinib, refametinib, pimasertib, cobimetinib, AZD8330, RO4987655, RO5126766, WX-554, E6201, PD-325901, CI-1040, GDC-0623, G-573, TAK-733, PD318088, PD98059, PD334581, 6-methoxy-7-(3-morpholin-4-yl-propoxy)-4-(4-phenoxy-phenylamino)quinoline-3-carbonitrile, and 4-[3-Chloro-4-(1-methyl-1H-imidazol-2-ylsulfanyl)phenylamino]-6-methoxy-7-(3-morpholin-4-yl-propoxy)-quinoline-3-carbonitrile.

Assignees

• Icahn School Med Mount Sinai

Inventors

• Dar Arvin
• Dhawan Neil
• Scopton Alex P

Classifications

• C07D239/93

  Sulfur atoms · CPC title

• A61K31/519

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61K31/517 Primary

  ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C07D239/74

  with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring · CPC title